Clinical Trial Update: Biomolecular Analysis for Predicting Response to Regorafenib [NA]

View source ↗

Summary

Completed clinical trial evaluating biomolecular markers to predict which glioblastoma patients respond to regorafenib, including the IDH-wildtype subtype.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioblastoma Idh-wildtype

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Conditions: Glioblastoma, Glioblastoma, IDH-wildtype | NA | Status: COMPLETED